Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPX4 | P36969 | 5/20 | 0.54 |
| ▸ | MGLL | Q99685 | 2/20 | 0.51 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.49 |
| ▸ | CACNB1 | Q02641 | 4/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.49 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5013045 | 0.86 | ALDH1A1 (0.57) | GPX4MGLLCACNA2D1CACNB1CACNA1B | |
| SCHEMBL5014235 | 0.83 | HSP90AA1 (0.64) | GPX4MGLLABHD6CACNA2D1CACNB1 | |
| SCHEMBL24496202 | 0.83 | GPX4 (0.53) | GPX4MGLLABHD6CACNA2D1CACNB1 | |
| SCHEMBL5011593 | 0.81 | TSHR (0.64) | GPX4MGLL | |
| SCHEMBL5009483 | 0.78 | USP2 (0.70) | MGLLCACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL3085217 | 0.76 | CES2 (0.52) | HDAC8 | |
| SCHEMBL3089158 | 0.75 | HDAC8 (0.50) | HDAC8 | |
| SCHEMBL917195 | 0.74 | GPX4 (0.69) | GPX4MGLLABHD6CACNA2D1CACNB1 | |
| SCHEMBL29944128 | 0.74 | TSHR (0.62) | HDAC8 | |
| SCHEMBL4752752 | 0.74 | NPSR1 (0.68) | CACNA2D1CACNB1CACNA1BCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306087-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | claimed |
| EP-1915355-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | claimed |
| WO-2007018459-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | claimed |
| US-20080306087-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306087-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306087-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| EP-1915355-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007018459-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007018459-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306087-A1 | Therapeutic Agents | NLN, BDNF, GAP43 | GPX4 341/4885MGLL 639/4885ABHD6 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.